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Gluconeogenesis is critical for maintenance of eugly-
cemia during fasting. Elevated gluconeogenesis dur-
ing type 2 diabetes (T2D) contributes to chronic
hyperglycemia. Pyruvate is a major gluconeogenic
substrate and requires import into the mitochondrial
matrix for channeling into gluconeogenesis. Here,
we demonstrate that the mitochondrial pyruvate car-
rier (MPC) comprising theMpc1 andMpc2 proteins is
required for efficient regulation of hepatic gluconeo-
genesis. Liver-specific deletion of Mpc1 abolished
hepatic MPC activity and markedly decreased pyru-
vate-driven gluconeogenesis and TCA cycle flux.
Loss of MPC activity induced adaptive utilization of
glutamine and increased urea cycle activity. Diet-
induced obesity increased hepatic MPC expression
and activity. Constitutive Mpc1 deletion attenuated
the development of hyperglycemia induced by a
high-fat diet. Acute, virally mediated Mpc1 deletion
after diet-induced obesity decreased hyperglycemia
and improved glucose tolerance. We conclude that
the MPC is required for efficient regulation of gluco-
neogenesis and that the MPC contributes to the
elevatedgluconeogenesis andhyperglycemia inT2D.
INTRODUCTION
Multicellular organisms have evolved complex processes for
systemic fuel recycling and maintenance of energy balance.CellAmong the most important of these in mammalian systems is
gluconeogenesis, a process whereby products of carbohydrate
and amino acid metabolism are condensed and replenished with
electrons to form glucose. Gluconeogenesis is critical during
prolonged fasting for maintenance of organismal function, espe-
cially of the CNS. The liver performs the large majority of whole-
body gluconeogenesis, with secondary contributions from the
kidneys. Despite being essential for survival, excessive gluco-
neogenesis drives disease, as typified by human patients with
type 2 diabetes (T2D). In T2D, elevated gluconeogenesis leads
to chronic hyperglycemia with devastating consequences,
including blindness, kidney failure, and cardiovascular events.
The mechanisms regulating gluconeogenesis are incom-
pletely understood, thereby limiting potential treatments for hy-
perglycemia. The enzyme phosphoenolpyruvate carboxykinase
(PEPCK) functions as the key control point of the canonical glu-
coneogenic pathway by catalyzing the committed step, the con-
version of oxaloacetate to phosphoenolpyruvate (Forest et al.,
1990). However, upstream factors involving mitochondrial meta-
bolism potently influence gluconeogenesis by regulating provi-
sion of oxaloacetate to PEPCK (Burgess et al., 2007).
The vast majority of gluconeogenic carbon flux is routed
through the mitochondrial matrix, and pyruvate is thought to
be the major mitochondrially imported substrate (Katz and
Tayek, 1999; Terrettaz and Jeanrenaud, 1990). Once in mito-
chondria, pyruvate is channeled toward gluconeogenesis by
carboxylation to oxaloacetate by the enzyme pyruvate carbox-
ylase. This reaction regulates oxaloacetate supply to PEPCK
and, therefore, the overall gluconeogenic rate. In T2D, elevated
hepatic b-oxidation drives gluconeogenesis by raising mito-
chondrial levels of reducing equivalents and acetyl-coenzyme
A (CoA), which allosterically activates pyruvate carboxylaseMetabolism 22, 669–681, October 6, 2015 ª2015 Elsevier Inc. 669
(Kumashiro et al., 2013; Merritt et al., 2011). Increased flux
through pyruvate carboxylase requires increased mitochondrial
pyruvate availability and, therefore, implicates increased activity
of the Mitochondrial Pyruvate Carrier (MPC) as a contributor to
the excessive gluconeogenesis in T2D.
The MPC conducts pyruvate across the mitochondrial inner
membrane to the matrix and thereby occupies a critical link be-
tween cytosolic andmitochondrial metabolism. Cytoplasmic py-
ruvate is derived from multiple sources in the cytosol, including
glycolysis and systemically produced lactate and alanine. Pyru-
vate diffuses freely across the mitochondrial outer membrane
through non-selective pores but, like other charged molecules,
requires specialized transport across the inner membrane.
Therefore, the MPC would be expected to gate pyruvate-driven
gluconeogenesis and, in T2D, import pyruvate at the higher rates
required for elevated gluconeogenesis.
Initial investigations of the MPC activity in ex vivo liver or kid-
ney systems found that chemical inhibition decreased gluconeo-
genesis (Halestrap and Denton, 1975; Mendes-Moura˜o et al.,
1975; Thomas and Halestrap, 1981). However, although the
MPC has been known as a specific, inhibitable biochemical ac-
tivity for over 40 years, the proteins of the MPC complex and the
genes that encode them remained unidentified until recently.
We and others recently discovered the molecular identity of
the MPC (Bricker et al., 2012; Herzig et al., 2012). The mamma-
lian MPC protein complex comprises two obligate, paralogous
subunits, designated MPC1 and MPC2, which are encoded by
the MPC1 and MPC2 genes and highly conserved across eu-
karyotes. MPC1 and MPC2 associate in a heteroligomer of
currently unknown but possibly dynamic stoichiometry (Bender
et al., 2015). Loss of either protein results in degradation of the
other and loss of MPC activity (Bricker et al., 2012; Herzig
et al., 2012; Vigueira et al., 2014).
The identification of the genes encoding theMPC now enables
in vivo, molecular-genetic studies on MPC function. We gener-
ated mice with liver-specific deletion of Mpc1 and investigated
the importance of the MPC for hepatic gluconeogenesis. We
found that theMPC gates pyruvate-driven hepatic gluconeogen-
esis. We observed that liver-specific disruption of the MPC
evokes broad changes in cellular- and systems-level meta-
bolism, including adaptive glutaminolysis in the liver and
decreased hyperglycemia in mouse models of T2D.
RESULTS
Mpc1 Liver-Specific Knockout Mice Display Gross
Changes in Metabolism and Maintain Fasting
Euglycemia
Mpc1 and Mpc2 proteins are expressed at relatively high levels
in the liver, the major site of gluconeogenesis (Figure 1A). To
investigate the function of the MPC in vivo for the regulation of
hepatic gluconeogenesis, we generated mice with a conditional,
floxed Mpc1 allele (Mpc1fl), which was functionally wild-type
(WT) (Figures S1A and S1B). We successively crossed Mpc1fl/fl
(WT) mice with mice expressing Cre under control of the albumin
promoter (Alb-Cre) (Postic et al., 1999), resulting in mice with
liver-specific Mpc1 deletion (Mpc1 LivKO) (Figure 1B). Loss of
Mpc1 protein was accompanied by loss of Mpc2 protein (Fig-
ure 1C), because Mpc1 protein is required for stable expression670 Cell Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier InofMpc2 protein and, therefore, loss of theMPCprotein complex.
Compared to WT mice, Mpc1 LivKO mice weighed slightly less
but displayed no differences in body composition (Figures S1C
and S1D), food intake (Figure 1D), and voluntary physical activity
(Figure 1E), suggesting the absence of a global energetic defect.
To investigate changes in gross metabolism, we measured
gas exchange (Figure 1F) and postabsorptive (4-hr food restric-
tion) and fasted (18-hr food restriction) serum parameters
(Table 1). Mpc1 LivKO mice manifested a decreased respiratory
exchange ratio (RER) during the dark cycle whenmost physically
active, increased ketones, decreased cholesterol, decreased
fasting triglycerides, and slightly but significantly elevated blood
lactate levels, all consistent with decreased gluconeogenesis
and increased hepatic and whole-body fat oxidation. Postab-
sorptive triglycerides were slightly increased. Liver triglycerides
and glycogen were not significantly different. Notably, AST/ALT
(aspartate transaminase/alanine transaminase) ratios were un-
changed, suggesting the absence of liver damage inMpc1 LivKO
mice. However, although fasting blood glucose levels of Mpc1
LivKO mice tended to be decreased, they were well within
normal ranges. Furthermore, glucose and insulin intolerance
were not changed (Figures 1G and 1H), and endogenous glucose
production was normal during fasting and suppressed normally
during euglycemic-hyperinsulinemic clamp with no change in
peripheral insulin sensitivity (Figures 1I–1K; Figure S1E). The
absence of an overt defect in glucose homeostasis raised two,
non-exclusive possibilities: first, that hepatic pyruvate-driven
gluconeogenesis remained intact by an MPC-independent
mechanism; and second, that increased gluconeogenesis
through an alternative pathway or site was compensating.
Hepatic Mitochondrial Pyruvate Uptake and Pyruvate-
Driven Respiration Are MPC Dependent
To begin to investigate the effects ofMpc1 deletion on pyruvate-
driven gluconeogenesis, we isolated mitochondria from WT and
Mpc1 LivKO mouse liver and measured 14C-radiolabeled pyru-
vate uptake. Importantly, this would test whether the protein
complex comprising Mpc1 and Mpc2 functions as the major
mitochondrial pyruvate carrier in liver, as we and others had pre-
viously shown in yeast, flies, and cultured fibroblasts (Bricker
et al., 2012; Herzig et al., 2012). Mpc1 LivKO mitochondria man-
ifested a complete loss of pyruvate uptake (Figure 2A). This result
extended to a test of mitochondrial function where pyruvate-
driven respiration by Mpc1 LivKO mitochondria was markedly
decreased at both higher (Figure 2B) or lower (Figure S2A)
pyruvate concentrations, which, respectively, increase MPC-
dependent or decrease MPC-independent respiration. MPC-
independent respiration occurs in in vitro assays because of
the super-endogenous pyruvate levels required for adequate
signal to noise (Pande and Parvin, 1978). The decrease in pyru-
vate oxidation by Mpc1 LivKO mitochondria was not amplified
by treatment with the MPC inhibitor 4-alpha-hydroxycinnamatic
acid (CHC) and matched that for WT mitochondria treated with
CHC, both consistent with inhibition of the Mpc1-Mpc2 complex
by CHC.
In a parallel experiment, glutamate oxidation, which is also
complex I dependent, was unaffected, providing evidence that
general mitochondrial respiratory function remained intact
despite the absence of the MPC (Figure 2C). Western blots ofc.
Figure 1. Generation and Basic Character-
ization of Mice with Liver-Specific Deletion
of Mpc1
(A) Western blot analysis of Mpc1 and Mpc2
protein abundance in lysates of C57Bl/6J mouse
tissues. Loading was normalized to total protein.
A reference protein is not shown because of
non-uniform expression among different tissues.
GA, gastrocnemius muscle; TA, tibialis anterior
muscle.
(B) Scheme illustrating generation of theMpc1 null
allele.
(C) Western blot analysis of Mpc1 and Mpc2
protein abundance in liver lysates from WT and
Mpc1 LivKO mice. Loading was normalized to
total protein, and actin is utilized as a reference
protein.
(D) Daily food intake byWT andMpc1 LivKOmice,
normalized to body weight (BW) (n = 8).
(E) Voluntary physical activity, measured by beam
breaks in CLAMS cages, of WT and Mpc1 LivKO
mice (n = 8).
(F) RER of WT and Mpc1 LivKO mice (n = 8).
(G and H) Glucose (G) and insulin (H) tolerance
tests comparing WT and Mpc1 LivKO mice. Blood
glucose was measured serially, and an area under
the curve (AUC) was calculated (n = 8).
(I) Glucose disposal rate (Rd) versus serum insulin
during the basal and hyperinsulinemic sampling
portions of the clamp (n = 5–6).
(J) Glucose appearance rate (Ra) versus serum
insulin during the basal and hyperinsulinemic
sampling portions of the clamp (n = 5–6).
(K) Insulin-stimulated uptake of 2-deoxyglucose
during the terminal hyperinsulinemic portion of
the clamp (n = 5–6). WAT, white adipose tissue;
BAT, brown adipose tissue; EDL, extensor dig-
itorum longus muscle; Gastroc, gastrocnemius
muscle.
Data are presented as means ± SEM (*p < 0.05;
**p < 0.01). See also Figure S1.liver (Figure 2D) or mitochondrial (Figure S2B) lysates for VDAC
and mitochondrial respiratory complex proteins showed no
changes, indicating that respiratory chain content was unaf-
fected by Mpc1 deletion. Collectively, these results demon-
strated that mitochondrial pyruvate uptake and pyruvate-driven
respiration are highly MPC dependent, whereas core respiratory
parameters are not.
Pyruvate-Driven Hepatic Gluconeogenesis Is MPC
Dependent
Because of the possibility of an MPC-independent mechanism
specialized for gluconeogenic mitochondrial pyruvate uptake,
we tested the importance of the MPC for pyruvate-driven
glucose production by cultured WT and Mpc1 LivKO mouse pri-
mary hepatocytes. Lactate, the reduced form of pyruvate, was
co-administered with pyruvate at a ratio of 10:1 to approximate
the intracellular ratio and minimize perturbation of redox state.
Mpc1 deletion resulted in a large decrease in glucose productionCellthat was not significantly decreased by treatment with the MPC
inhibitor UK-5099 (Figure 3A). This result demonstrated that
the MPC gates pyruvate-driven gluconeogenesis in cultured
hepatocytes.
Because Mpc1 LivKO mice maintained fasting euglycemia,
potentially by increased utilization of non-pyruvate substrates,
we sought to more specifically test the in vivo importance of
the MPC for pyruvate-driven gluconeogenesis. We performed
a lactate/pyruvate tolerance test (L/PTT) by intraperitoneal injec-
tion of 18-hr-fasted WT and Mpc1 LivKO mice. Blood glucose
excursion and lactate clearance were strikingly decreased in
Mpc1 LivKO mice (Figures 3B and 3C), consistent with impaired
pyruvate-driven gluconeogenesis. We observed similar results
with female mice (Figures S2C and S2D).
We next utilized universally (U)13C-labeled lactate and pyru-
vate tracers to measure pyruvate incorporation into glucose.
Here, each of the three carbon atoms of lactate or pyruvate is
the stable 13C isotope, resulting in a 3-Da mass increaseMetabolism 22, 669–681, October 6, 2015 ª2015 Elsevier Inc. 671
Table 1. Serum and Liver Parameters
Parameter
4-hr Fast 18-hr Fast
WT LivKO WT LivKO
Serum
Insulin (ng/ml) 0.68 ± 0.03 0.69 ± 0.03 0.18 ± 0.01 0.16 ± 0.02
Triglycerides (mg/dl) 50.0 ± 1.2 57.7 ± 1.8** 75.0 ± 6.2 51.3 ± 2.0**
NEFAs (mEq/l) 0.84 ± 0.04 0.92 ± 0.06 1.09 ± 0.07 0.89 ± 0.03
Cholesterol (mg/dl) 145.3 ± 4.9 122.6 ± 4.3** 142.4 ± 4.1 119.0 ± 3.8**
Ketones (mmol/l) 191.0 ± 22.0 355.2 ± 16.9** 708.1 ± 42.6 1006.6 ± 31.8*
Lactate (mmol/l) 2.24 ± 0.16 2.75 ± 0.16* 1.19 ± 0.05 1.94 ± 0.14**
Glucose (mg/dl) 148.6 ± 5.3 132.4 ± 4.1* 94.1 ± 4.2 88.8 ± 5.6
AST/ALT 1.75 ± 0.14 1.77 ± 0.14 1.84 ± 0.12 1.85 ± 0.12
Liver
Triglycerides (mg/g) 10.0 ± 1.27 11.5 ± 0.9 48.1 ± 2.6 51.2 ± 1.9
Glycogen (glucose; mmol/g) 87.3 ± 15.3 65.7 ± 16.7 30.7 ± 4.8 31.7 ± 4.0
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01. NEFAs, non-esterified fatty acids.(M+3). WT and Mpc1 LivKO mice were administered U13C-
lactate and -pyruvate by intraperitoneal injection as performed
previously (Potthoff et al., 2011). To capture flux data under
near-equilibrium gluconeogenic conditions, livers were har-
vested and immediately freeze-clamped at 30 min post-injec-
tion, the expected time of plateau for blood glucose and lactate
concentrations. The most direct flux of U13C-pyruvate into
glucose yields the M+3 glucose isotopomer. Metabolomic anal-
ysis of hepatic extracts revealed a markedly lower concentration
of M+3 glucose in Mpc1 LivKO mice (Figure 3D). Results were
highly similar for the M+2 and total labeled glucose pools, as
complementary measures of flux (Table S1). These results pro-
vided direct evidence that hepatic pyruvate-driven gluconeo-
genesis isMPC dependent. Nonetheless, the important question
remained of howMpc1 LivKOmice maintain fasting euglycemia.
Mpc1Deletion Results in Impaired Pyruvate-Driven TCA
Cycle Flux
To identify a potential adaptive pathway by which Mpc1 LivKO
mice sustained gluconeogenesis, we extended our flux metabo-
lomics analysis to tricarboxylic acid (TCA) cycle intermediates.
For all intermediates analyzed, which were citrate, a-ketogluta-
rate (AKG), succinate, fumarate, malate, and oxaloacetate, frac-
tional abundance of the M+3 isotopomer was decreased in
Mpc1 LivKO mice, consistent with decreased flux of pyruvate
into the TCA cycle (Table S1). However, analysis of absolute
M+3 isotopomer concentrations revealed a striking pattern that
implicated increased amino acid influx through AKG as a poten-
tial adaptation to loss of MPC activity. First, concentrations of
M+3 lactate and pyruvate were increased (Figure 4A). Second,
M+3 concentrations of citrate, succinate, fumarate, malate,
and oxaloacetate were decreased. Third, and in contrast, M+3
concentrations of AKG were not significantly decreased. With
closer examination, greater absolute AKG concentrations were
offsetting a decreased M+3 fractional enrichment (Table S1), re-
sulting in M+3 AKG concentrations similar to those of WT. As
with glucose, this pattern persisted through the M+2 and total
labeled pools (Table S1). These findings suggested that pyruvate
and lactate accumulated because of decreased mitochondrial672 Cell Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier Inpyruvate uptake and that pools of citrate, succinate, fumarate,
malate, and oxaloacetate were strongly MPC dependent, but
that a significant component of the AKG pool was MPC
independent.
We speculated that inflation of the AKG pool in Mpc1 LivKO
mice signified increased anaplerotic flux of glutamine into the
TCA cycle. We previously showed that fibroblasts isolated
from a human patient with an inactivating MPC1 mutation dis-
played normal glutamine oxidation (Bricker et al., 2012; Brivet
et al., 2003). Here, we observed that Mpc1 LivKO mitochondria
oxidized glutamate at normal rates (Figure 2C). Glutaminolysis
is a hallmark of many cancer cells and occurs concomitantly
with aerobic glycolysis, which may be promoted by loss of
MPC activity (Schell et al., 2014). In cell culture systems, gluta-
mate-dehydrogenase-dependent glutaminolysis was increased
after disruption of the MPC (Vacanti et al., 2014; Yang et al.,
2014). Therefore, we extended our flux metabolomic analysis
to glutamate and glutamine and found that, as with AKG, 13C-
labeled concentrations were not decreased in Mpc1 LivKO
mice, consistent with AKG flux predominating from glutamine
rather than pyruvate (Figure 4A; Table S1).
Mpc1 Deletion Decreases Steady-State Fasting Hepatic
Glutamine Concentrations Concomitant with Increased
Markers of Urea Cycle Activity
To further investigate the adaptive metabolism by which Mpc1
LivKO mice maintain euglycemia during fasting, we performed
broad, steady-state metabolomic analysis comparing WT and
Mpc1 LivKO mouse livers after 18 hr of fasting. A total of 118
known metabolites were measured from major hepatic meta-
bolic programs, including the TCA cycle; glycolysis; the pentose
phosphate pathway; the urea cycle; and general amino acid,
lipid, and nucleotide metabolism (Table S2). We expected that
this experiment would complement our pyruvate-driven flux
metabolomics experiments by capturing larger steady-state pat-
terns of compensation. Indeed, principal-component analysis
(Xia et al., 2012) of aggregate metabolomic data demonstrated
that WT and Mpc1 LivKO hepatic metabolisms are systemati-
cally distinct (Figure S3A).c.
Figure 2. Effects of Mpc1 Deletion on Hepatic Mitochondrial Pyru-
vate Metabolism
(A) 14C-pyruvate uptake by liver mitochondria isolated from WT and Mpc1
LivKO mice (n = 4).
(B) Pyruvate-driven (10 mM pyruvate/2 mM malate) respiration by liver mito-
chondria isolated from WT and Mpc1 LivKO mice (n = 4). ROT = rotenone.
(C) Glutamate-driven (10 mM glutamate/2 mM malate) respiration by liver
mitochondria isolated from WT and Mpc1 LivKO mice (n = 4).
(D) Western blot analysis of electron transport chain (ETC) components
(Complexes I–V) and Mpc1, Mpc2, VDAC, and HSP90 proteins in liver lysates
from WT and Mpc1 LivKO mice. Densitometric quantification is relative to
HSP90.
Data are presented as mean ± SEM (*p < 0.05; **p < 0.01). See also Figure S2.
Figure 3. Lactate/Pyruvate-Driven Gluconeogenesis Is MPC
Dependent
(A) Lactate/pyruvate-driven gluconeogenesis by primary hepatocytes isolated
fromWT and LivKOmice, in the presence of theMPC-inhibitor UK5099 (UK) or
vehicle (Veh) (n = 3).
(B and C) Blood (B) glucose excursion and (C) lactate clearance in WT and
Mpc1 LivKO mice during an L/PTT. Blood glucose and lactate were measured
serially, and AUCs were calculated (n = 8).
(D) M+3 glucose concentrations in liver tissue from WT and Mpc1 LivKO mice
following administration of U13C-labeled lactate/pyruvate (n = 6).
Data are presented as mean ± SEM (*p < 0.05; **p < 0.01).Analysis of individual metabolites revealed changes in Mpc1
LivKO livers consistent with decreased pyruvate and increased
glutamine flux into the TCA cycle. Lactate and pyruvate
were significantly increased (Figure 4B). Glycolytic and pentose
phosphate pathway intermediates were unchanged or in-
creased, consistent with increased mass-action-driven shunting
of glucose into cytosolic metabolism because of impairedCell Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier Inc. 673
Figure 4. Glutaminolysis and Pyruvate Transformations Enable MPC-Independent Gluconeogenesis
(A) Ratios of absolute M+3 isotopomer concentrations in Mpc1 LivKO versus WT livers (LivKO/WT) following administration of U13C-labeled lactate/pyruvate (n =
5–6). LAC, lactate; PYR, pyruvate; ALA, alanine; ASP, aspartate; OaA, oxaloacetate; CIT, citrate; a-KG, AKG; SUC, succinate; FUM, fumarate; MAL,malate; GLN,
glutamine; GLU, glutamate.
(B) Relative steady-state abundance of select metabolites in Mpc1 LivKO versus WT livers (LivKO/WT) after 18-hr fasting (n = 7–9).
(C) Glutamine-driven gluconeogenesis by mouse primary hepatocytes isolated fromWT andMpc1 LivKOmice in the presence of theMPC-inhibitor UK5099 (UK)
or vehicle (Veh) (n = 3).
(legend continued on next page)
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downstream flux into mitochondria (Figure S3B). Notably, con-
centrations of TCA cycle intermediates were generally un-
changed, indicating, independent of rates of flux, that pool sizes
were maintained (Figure S3B). However, AKG was a distinctive
outlier with a marked increase in concentration (Figure 4B).
Glutamine and aspartate, but not other protein-coding amino
acids, were significantly decreased (Figure 4B; Figure S3B),
consistent with findings of glutamine as a source of AKG. Intrigu-
ingly, we observed significant increases in urea, ornithine, and
N-acetyl-glutamate (Figure 4B), the obligate activator of the
rate-limiting enzyme of the urea cycle, carbamoyl phosphatase.
However, this was not surprising, because increased urea cycle
activitywould scavenge the ammonia produced by the increased
deamination of glutamine to AKG. Combined with fluxmetabolo-
mic data where Mpc1 LivKO livers exhibited inflation of an MPC-
independent AKG pool with an enrichment pattern similar to
those of glutamate and glutamine, these data suggested that
increased glutaminolysis in Mpc1 LivKO mice decreases gluta-
mine concentrations, drives increased AKG concentrations,
and generates an ammonia load that activates the urea cycle.
Glutamine Supports Robust MPC-Independent
Gluconeogenesis
To test the efficacy of glutamine as an MPC-independent gluco-
neogenic substrate, we measured glutamine-driven gluconeo-
genesis by WT and Mpc1 LivKO primary mouse hepatocytes.
It was not significantly decreased by MPC chemical inhibition
or Mpc1 deletion (Figure 4C). Moreover, glutamine supported a
higher rate of glucose production than pyruvate (Figures 3A
and 4C). To assess in vivo relevance, we performed an intraper-
itoneal glutamine tolerance test (QTT) with WT and Mpc1 LivKO
mice. In contrast to results observed with lactate/pyruvate,
glutamine-driven glucose excursion in Mpc1 LivKO mice was
not impaired (Figure 4D). Interpreted together, these results
demonstrated that glutamine robustly supports MPC-indepen-
dent hepatic gluconeogenesis.
Next, we investigated potential mechanisms for MPC-inde-
pendent, pyruvate-driven gluconeogenesis. Though our primary
hepatocyte and in vivo flux metabolomic data convincingly
demonstrated that loss of MPC activity decreased pyruvate-
driven gluconeogenesis, 13C-label from pyruvate continued to
be incorporated into glucose, indicating persistence of MPC-
independent pyruvate-driven gluconeogenesis. Furthermore, in
isolated mouse primary hepatocytes, neither genetic disruption
nor chemical inhibition of the MPC eliminated pyruvate-driven
gluconeogenesis (Figure 3A). We considered the possibility of
cytosolic pyruvate conversions to metabolites that would not
require the MPC to enter mitochondria.
Pyruvate is interchangeable to alanine or malate by single re-
actions, catalyzed by ALT or malic enzyme (ME), respectively,
in both the cytosol andmitochondria. Thus, transformation of py-(D) QTT comparing WT and Mpc1 LivKO mice. Blood glucose was measured s
(E) Gluconeogenesis by rat primary hepatocytes, supported by different substrate
or both. L/P, 4.5 mM lactate/0.5 mM pyruvate; L/P+Gln, 2.25 mM lactate/0.25 mM
2.5 mM alanine; L/P+Mal, 2.25 mM lactate, 0.25 mM pyruvate, and 2.5 mM mala
(F) Model for pyruvate transformations to alanine and malate as MPC bypasses
(cytosolic/mitochondrial); Mdh1/2, malate dehydrogenase (cytosolic/mitochond
Data are presented as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001). See also
Cellruvate to alanine ormalate could enable pyruvate-derived carbon
to entermitochondria independently of theMPC. To examine this
possibility, we performed gluconeogenesis assays with isolated
primary rat hepatocytes treated with vehicle, the MPC inhibitor
UK-5099, the ALT inhibitor b-chloro-alanine (Beuster et al.,
2011), or UK-5099 and b-chloro-alanine combined.
Glutamine, alanine, and malate all supported MPC-indepen-
dent gluconeogenesis, although with varying capacities (Fig-
ure 4E). As with mouse primary hepatocytes, lactate/pyruvate-
driven gluconeogenesis was markedly decreased by MPC
inhibition. ALT inhibition alone exerted a mild but statistically
significant effect. CombinedMPCandALT inhibition dramatically
decreased gluconeogenesis. In contrast, a combined lactate/
pyruvate+glutaminecocktail supported robust gluconeogenesis
that was insensitive to MPC, ALT, or combined inhibition. Similar
results were obtained with the administration of glutamine
without lactate/pyruvate. These two results provided evidence
for selective utilization of glutamine frommedia rich in lactate/py-
ruvate to support MPC-independent gluconeogenesis.
Pyruvate Transformations as aMechanism for Pyruvate-
Driven, MPC-Independent Gluconeogenesis
Interestingly, a combined lactate/pyruvate and alanine cocktail
led to a gluconeogenic rate similar to that for lactate/pyruvate
alone, which was not significantly decreased with either MPC
or ALT inhibition but was markedly decreased by combined
MPC and ALT inhibition (Figure 4E). A similar pattern was
observed for alanine alone but with lesser gluconeogenic rates.
Together, these results and those with lactate/pyruvate alone
provide evidence for pyruvate-alanine cycling as an MPC
bypass, where pyruvate may be transaminated to alanine by
the cytosolic ALT, imported into mitochondria, and deaminated
to pyruvate by the mitochondrial ALT (Figure 4F), as demon-
strated in vivo by McCommis et al. (2015).
Similar to glutamine,malate alone supported gluconeogenesis
that was insensitive to MPC or ALT inhibition but at a lesser rate,
closely matching that of alanine (Figure 4E). NADP+-dependent
regulation of cytosolic ME strongly favors malate; therefore,
pyruvate would not be expected to be converted to malate at
high rates. Nonetheless, the fraction of lactate/pyruvate-driven
gluconeogenesis insensitive to combined MPC and ALT inhibi-
tion, although minimal, was greater than that observed for
alanine and similar to that for malate alone. This raises the pos-
sibility that a minor fraction of MPC-independent, pyruvate-
driven gluconeogenesis may be supported by pyruvate-malate
interconversions (Figure 4F).
Consideration of Additional Adaptive Responses to Loss
of Hepatic MPC Activity
We considered whether changes in hepatic gene expression
could contribute to the altered metabolism and serumerially, and an area under the curve (AUC) was calculated (n = 9).
s and treated with vehicle, the MPC inhibitor UK5099, the ALT inhibitor b-ClA,
pyruvate + 2.5 mM glutamine; L/P+Ala, 2.25 mM lactate/0.25 mM pyruvate +
te; Gln, 5 mM glutamine; Ala, 5 mM alanine; Mal, 5 mM malate (n = 3).
. Me1/2, malic enzyme (cytosolic/mitochondrial); Alt1/2, alanine transaminase
rial).
Figure S3 and Tables S1 and S2.
Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier Inc. 675
parameters observed in Mpc1 LivKO mice. We examined tran-
script abundance by qPCR for components of key metabolic
pathways, including gluconeogenesis (Fbp1, G6pc, Pck1,
Ppargc1a, Pc), de novo lipogenesis (Acly, Acaca, Fasn, Srebf1,
Scd1), fatty-acid oxidation (Acox1, Cpt1a, Echs1, Hadha), and
ketogenesis (Bdh1, Bdh2, Hmgcs1), as well as for Gls2, the he-
patocyte-specific isoform of glutaminase, in ad-libitum-fed and
18 hr-fasted WT and Mpc1 LivKO mice (Figure S4). No signifi-
cant differences were observed between genotypes within the
fed or fasted states for enzymes for gluconeogenesis, lipogen-
esis, and fatty-acid oxidation, or for glutaminase. We note that
fasting was accompanied by significant increases in Fbp1,
Pck1, Ppargc1a, and Pc, consistent with transcriptional upre-
gulation of gluconeogenesis, but an unexpected decrease in
G6pc. This decrease in G6pc was tested and observed again
with two additional primer pairs and again with fresh RNA iso-
lates and cDNA preparations, suggesting that the regulation of
G6pc is complex and extends beyond feeding status. Under
fasting conditions, the abundance of transcripts for ketogen-
esis or fatty-acid oxidation was decreased or not different in
Mpc1 LivKO mice compared to WT mice. This finding is diver-
gent from the increased serum ketones observed in Mpc1
LivKO mice (Table 1), suggesting that fatty-acid oxidation and
ketogenesis may be increased by regulatory changes in
enzyme specific activities or mass-action forces resulting
from loss of MPC activity.
Finally, because renal gluconeogenesis can compensate for
impaired hepatic gluconeogenesis, we measured Pck1 and
G6pc transcript abundance in the kidney cortex. Kidney cortex
levels of both Pck1 and G6pc increased with fasting. Increases
were significantly greater in Mpc1 LivKO compared to WT
mice, consistent with potential compensatory upregulation of
supplemental renal gluconeogenesis (Figure S4).
Constitutive Loss of Hepatic MPC Activity Attenuates
Development of Hyperglycemia and Glucose
Intolerance with High-Fat Diet-Induced Obesity
We reasoned that the MPC might be limiting for the higher rates
of gluconeogenesis induced in mice by a high-fat diet (HFD), a
model for human T2D. WT and Mpc1 LivKO littermates were
placed on an HFD at age 10 weeks, and weight was measured
weekly. Postabsorptive blood glucose and insulin were
measured every third week. Both groups gained weight at equal
rates (Figure 5A). Postabsorptive blood glucose levels were
similar through 6 weeks but diverged by 9 weeks, with blood
glucose levels lower in Mpc1 LivKO mice (Figure 5B). No signif-
icant differences in insulin concentrations were observed (Fig-
ure 5C). Analysis of additional post-absorptive and fasting serum
parameters following 12 weeks HFD revealed increased post-
absorptive ketones and triglycerides and fasting lactate in
Mpc1 LivKO mice (Figure S5A). Differences were not observed
in other parameters. Mpc1 LivKO mice manifested superior
intraperitoneal glucose tolerance (Figure 5D) without changes
in insulin tolerance (Figure 5E), suggesting that differences in
glucose tolerance were not a result of improved peripheral
insulin sensitivity. Together, these results demonstrated that
constitutive, liver-specific loss of MPC activity attenuated the
development of hyperglycemia and glucose intolerance induced
by a high-fat feeding.676 Cell Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier InAcute Mpc1 Deletion after Diet-Induced Obesity
Attenuates Hyperglycemia and Improves Glucose
Tolerance
To genetically recapitulate pharmacological liver-specific inhi-
bition and bypass potential developmental adaptations, we
next considered whether acute adeno-associated virus
(AAV)-mediated hepatic Mpc1 deletion after entrenched diet-
induced obesity would improve glucose homeostasis. Litter-
mate Mpc1fl/fl (WT) mouse pairs were divided into groups to
be treated with AAV-Cre or -GFP, expressed from the hepato-
cyte-specific TBG promoter (Yan et al., 2012). Mice were
placed on an HFD for 22 weeks, evaluated for glucose homeo-
stasis, treated with AAV-Cre or -GFP by retro-orbital injection
(Figure 5F), and re-evaluated for glucose homeostasis. Prior
to AAV administration, no differences were observed between
groups that were to receive AAV-Cre or -GFP for glucose toler-
ance (Figure 5G), insulin tolerance (Figure 5H), and blood
glucose excursion (Figure S5B) or lactate clearance (Fig-
ure S5C) during an L/PTT.
AAV-Cre, but not AAV-GFP, resulted in highly efficient Mpc1
deletion (Figure S5D). Acute Mpc1 deletion led to improved
glucose (Figure 5I) and insulin (Figure 5J) tolerance. During an
L/PTT, blood glucose excursion significantly decreased (Fig-
ure S5E), with a strong trend toward decreased lactate clear-
ance (Figure S5F). Furthermore, acute Mpc1 LivKO mice man-
ifested significantly decreased blood glucose values after 4, 6,
and 18 hr fasting (Figure 5K). The decrease in blood glucose
with 18 hr fasting was accompanied by a significant decrease
in insulin concentrations (Figure 5L). Serum triglycerides were
not changed postabsorptively (Figure S5G) but were increased
after fasting (Figure S5H). No differences were observed in fast-
ing ketones, lactate, or the AST/ALT ratio (Figure S5H); in the
hematoxylin-and-eosin-stained section lipid droplet area (Fig-
ure S5I); in fasting liver triglycerides (Figure S5J); or in body
weight (Figure S5K). These results demonstrated that acute
liver-specific disruption of MPC activity after longer term diet-
induced obesity attenuated hyperglycemia and improved
glucose homeostasis.
Diet-Induced Obesity Increases Hepatic MPC
Expression and Activity
Next, we investigated whether diet-induced obesity increased
MPC activity in the liver. The rationale for this experiment
was two-fold. First, pyruvate-driven gluconeogenesis is
increased during T2D, which could be partially driven by
increased MPC activity. Second, our observations that
Mpc1 deletion in obese, but not lean, mice decreased blood
glucose levels suggested that the MPC may be required for a
portion of the increased gluconeogenesis during diet-induced
obesity. We isolated liver mitochondria from age-matched
control mice fed an HFD or normal chow for 22 weeks and
measured the uptake of 14C-radiolabeled pyruvate and rates
of pyruvate and glutamate oxidation. MPC activity was signif-
icantly increased with diet-induced obesity (Figure 6A). In
contrast, neither pyruvate (Figure 6B) nor glutamate (Fig-
ure 6C) oxidation was increased. Similarly, mitochondrial py-
ruvate oxidation supported by lower pyruvate concentrations
was not increased with 17 weeks of high-fat feeding
(Figure S6A).c.
Figure 5. Both Constitutive and AcuteMpc1
Deletion Attenuates Hyperglycemia and
Glucose Intolerance during HFD-Induced
Obesity
(A) Bodyweights ofWT andMpc1 LivKOmice over
12 weeks of HFD feeding (n = 10).
(B andC) Postabsorptive blood (B) glucose and (C)
insulin levels of WT and Mpc1 LivKO mice over
12 weeks of HFD (n = 10).
(D and E) Glucose (D) and insulin (E) tolerance tests
(GTT and ITT, respectively) comparing WT and
Mpc1 LivKO mice after 12 weeks of HFD. Blood
glucose was measured serially, and an AUC was
calculated. (n = 10).
(F) Schema illustrating the time course of high-fat
feeding, tolerance test (TT) administration, and
AAV-GFP/Cre administration for Mpc1fl/fl mice.
(G and H) Glucose (G) and insulin (H) tolerance
tests comparing groups of HFD Mpc1fl/fl before
treatment with either AAV-GFP or AAV-Cre. Blood
glucose was measured serially, and an AUC was
calculated (n = 10).
(I and J) Glucose (I) and insulin (J) tolerance tests
comparing groups of HFD Mpc1fl/fl mice after
treatment with either AAV-GFP or AAV-Cre and
hepatocyte-specific Mpc1 deletion in AAV-Cre-
treated mice. Blood glucose was measured seri-
ally, and an AUC was calculated (n = 10).
(K) Blood glucose levels in AAV-GFP- andAAV-Cre-
treatedmiceafter 0, 4, 6, and18hrof fasting (n=10).
(L) Serum insulin levels in AAV-GFP- and AAV-Cre-
treated mice after 0, 6, and 18 of fasting (n = 5–10).
Data are presented asmean ± SEM (*p < 0.05; **p <
0.01). See also Figure S5.We considered whether increased MPC activity resulted from
increased MPC expression. Analysis by qPCR revealed that
Mpc1, but not Mpc2, transcript abundance increased with
diet-induced obesity (Figure 6D). Interestingly, western blots of
whole liver lysates showed that levels of both Mpc1 and Mpc2
protein increased (Figure S5B), raising the possibility that the
increased Mpc1 protein stabilizes and post-transcriptionally
increases levels of Mpc2 protein. Western blots of isolated
mitochondria showed marked increases in VDAC-normalized
Mpc1 and Mpc2 protein, with smaller or no increases in markers
of the mitochondrial respiratory chain (Figure 6E). We evaluated
whether fasting induced similar increases in MPC activity, but
none were observed (Figure S5C), suggesting that regulation
by fasting may bemore complex. Overall, these findings demon-
strated that diet-induced obesity resulted in increased MPC ac-
tivity relative to mitochondrial respiratory capacity, a decoupling
that could contribute to increased gluconeogenic drive.Cell Metabolism 22, 669–681DISCUSSION
Gluconeogenesis is an important process
for maintaining blood glucose levels dur-
ing carbohydrate scarcity, and pyruvate
is thought to be the major in vivo sub-
strate. Here, we tested the functional
importance of the MPC encoded by the
Mpc1 andMpc2 genes for hepatic gluco-neogenesis. We demonstrate that the MPC is critical for hepatic
mitochondrial pyruvate uptake and gates pyruvate-driven hepat-
ic gluconeogenesis in vivo. These findings link the Mpc1 and
Mpc2 genes to a fundamental in vivo function at the intersection
of cytosolic and mitochondrial metabolism.
Our findings demonstrate the importance of the MPC for effi-
cient regulation of hepatic gluconeogenesis. Pyruvate robustly
supports gluconeogenesis and mitochondrial metabolism
because it can be converted by single reactions to oxaloacetate
or acetyl-CoA, the keystone pair of intermediates required to
sustain TCA cycle flux. Glutamine may also be utilized to pro-
duce oxaloacetate and acetyl-CoA but by several reactions
and with decreased energetic yield (Yang et al., 2014). Thus,
as we observed when MPC activity is lost, regulated increases
in gluconeogenesis during fasting that are most efficiently sup-
ported by pyruvatemay be adaptively supported by less efficient
and ammoniagenic glutaminolysis., October 6, 2015 ª2015 Elsevier Inc. 677
Figure 6. Diet-Induced Obesity Increases Hepatic MPC Protein
Levels and Activity
(A) 14C-pyruvate uptake by liver mitochondria isolated from HFD-fed versus
age-matched normal-chow-fed control mice (n = 8). NCD, normal chow diet.
(B and C) Shown here, (B) pyruvate-driven (10 mM pyruvate/2 mMmalate) and
(C) glutamate-driven (10 mM glutamate/2 mM malate) respiration by liver
mitochondria isolated from HFD-fed versus age-matched normal-chow-fed
control mice (n = 8).
(D) RelativeMpc1 andMpc2 transcript abundance in livers of HFD-fed versus
age-matched normal-chow-fed control mice, normalized to U36b4 (n = 8).
(E) Western blot analysis of electron transport chain (ETC) components
(Complexes I–V) and Mpc1, Mpc2, VDAC, and HSP90 proteins in liver lysates
from HFD-fed versus age-matched normal-chow-fed control mice. Densito-
metric quantification is relative to HSP90 (n = 8).
All mice were on an HFD for 22 weeks from 6weeks of age. Data are presented
as mean ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001). See also Figure S6.Our results illustrate fundamental distinctions between the
function of the MPC and the canonical regulators of gluconeo-
genesis G6pase and PEPCK. First, G6Pase is required for the
final step of gluconeogenesis, and loss of hepatic G6Pase re-
sults in hyperaccumulation of glycogen concomitant with fasting
hypoglycemia (Mutel et al., 2011). Second, PEPCK is required for678 Cell Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier InTCA cycle flux into gluconeogenesis but, when disrupted, may
be circumvented by glycerol-supported gluconeogenesis at
the cost of impaired fatty acid oxidation and severe fasting stea-
tosis (Burgess et al., 2004). Disruption of the MPC imposes
neither of these limitations and, as we observed, resulted in
neither hepatic glycogen nor lipid accumulation.
Similar distinctions emerge when comparing the MPC to
the well-characterized regulators of mitochondrial pyruvate
metabolism, pyruvate dehydrogenase (PDH), and pyruvate
carboxylase. PDH is required for conversion of pyruvate to
acetyl-CoA and essential for glucose oxidation and high rates
of amino acid oxidation. Pyruvate carboxylase is required for
direct conversion of pyruvate to oxaloacetate for gluconeogen-
esis and important for sustaining overall TCA cycle flux.
In experiments with Mpc1 LivKO mice, we observed
decreased but persistent flux of U13C-pyruvate into both the
M+2 and M+3 isotopomers of TCA-cycle intermediates.
Because the M+2 andM+3 isotopomers are markers of PDH ac-
tivity and the M+3 isotopomer is a marker of pyruvate carbox-
ylase activity, these data indicate that flux through both PDH
and pyruvate carboxylase persists when MPC activity is lost.
Thus, whereas loss of PDH activity abolishes acetyl-CoA pro-
duction from non-lipid substrates, substrate transformations to
pyruvate within mitochondria enable MPC-independent PDH
activity.
Our findings suggest that the liver’s high capacity for fatty-
acid oxidation and ketogenesis is used to compensate for
loss of MPC activity. The decreased serum cholesterol and fast-
ing triglycerides, increased serum ketones, and decreased
dark-period RER we observed in Mpc1 LivKO mice are all
consistent with increased hepatic fatty-acid oxidation and
decreased lipid synthesis. This is congruent with the increased
fatty-acid oxidation induced in cultured myoblasts with MPC
knockdown (Vacanti et al., 2014) and likely a general adaptive
measure for impaired mitochondrial carbohydrate utilization.
Thus, our data support a model for an overall adaptive meta-
bolism where loss of the MPC constrains pathways for mito-
chondrial pyruvate metabolism and mitochondrially routed
gluconeogenesis to those utilizing amino acids and pyruvate
transformations, where fatty-acid oxidation is increased to
compensate for decreased mitochondrial pyruvate availability,
and where decreased flux of pyruvate through PDH decreases
mitochondrial citrate available for efflux into fatty-acid and
cholesterol synthesis.
Our data demonstrating that disruption of the MPC improves
glucose homeostasis during diet-induced obesity and leads to
favorable changes in lipidmetabolism recapitulates desired ther-
apeutic outcomes. This raises the question of whether the hepat-
ic MPC may be therapeutically modulated. Indeed, targeting he-
patic mitochondria to treat metabolic disease has strong
historical and emerging precedent. Metformin, the most widely
used and staple treatment for T2D, decreases hepatic gluconeo-
genesis by perturbing mitochondrial metabolism. Although the
precise mechanism remains without consensus, the well-char-
acterized therapeutic effects of metformin provide a convincing
demonstration of the potential efficacy of mitochondrial target-
ing (Madiraju et al., 2014; Miller et al., 2013). As another example,
recent findings demonstrate that liver-specific delivery of a mito-
chondrial uncoupler reversed steatohepatitis and symptoms ofc.
diabetes in rats (Perry et al., 2015). More specifically, thiazolidi-
nediones have recently been shown to inhibit MPC activity, pre-
senting the possibility that a portion of their therapeutic effect
could result from inhibition of the hepatic MPC (Divakaruni
et al., 2013).
Nonetheless, critical considerations must be addressed to
determine whether inhibiting the hepatic MPC is a viable thera-
peutic strategy. The increases in urea cycle activity and blood
ketones and slight increases in blood lactate we observed are
of unknown clinical significance, especially when considered in
the context of more severe disease or stress conditions such
as chronic kidney disease, extreme exertion, liver injury, or
cancer. The decreased mitochondrial pyruvate utilization and
increased glutaminolysis withMpc1 LivKO recapitulates aspects
of the transformed metabolism observed in many cancers
(Schell et al., 2014; Vacanti et al., 2014; Yang et al., 2014) and
could provide a favorable metabolism for tumorigenesis during
at-risk states such as fatty-liver disease or steatohepatitis.
Furthermore, disruption of MPC activity in tissues with a lesser
capacity for fatty-acid oxidation than the liver, such as those of
the CNS, could be lethal, as was observed for a human patient
with an inactivating mutation inMPC1 (Bricker et al., 2012; Brivet
et al., 2003).
The increase in hepatic MPC expression and activity that we
observed with diet-induced obesity may drive increased mito-
chondrial pyruvate import and, therefore, elevated gluconeogen-
esis during T2D. That the MPC is a carrier rather than a channel
and, therefore, imposes a kinetic barrier suggests an evolu-
tionary requirement for limiting the rate of pyruvate entry into
mitochondria. This would enable metabolic control beyond that
provided directly by regulation of pyruvate carboxylase and
PDH. Given that capacity for hepatic pyruvate oxidation in vivo
has an upper limit well below that for anaplerotic pyruvate flux,
a potential evolutionary basis for controlling uptake is to control
anaplerotic flux. From this perspective, an imbalance between
mitochondrial pyruvate uptake and oxidation would be expected
to proportionally drive gluconeogenesis. This precise phenome-
non is observed in T2D and consistent with the increased MPC
expression and activity that we observed in a mouse model
of T2D.
In conclusion, our results demonstrate that the MPC is
required for efficient regulation of hepatic gluconeogenesis and
whole-body glucose homeostasis. Mpc1 LivKO mice employed
adaptive increases in glutaminolysis to sustain fasting euglyce-
mia that elicited increases in urea cycle activity. Inmousemodels
of T2D, compensatory responses to constitutive or acute MPC
disruption were insufficient to sustain elevated blood glucose
levels. Disruption of the hepatic MPC causes inefficient regula-
tion of gluconeogenesis and broad changes in cellular- and sys-
tems-level metabolism that decrease hyperglycemia in mouse
models of T2D.
EXPERIMENTAL PROCEDURES
Animals and Animal Care
Animal work was performed in accordance with the University of Iowa Animal
Care and Use Committee (IACUC). Unless otherwise stated, all experiments
were performed with 8- to 12-week-old male C57Bl/6 mice. C57Bl/6J mice
were purchased from Jackson Laboratories. Sprague-Dawley rats were pur-
chased from Harlan Laboratories.CellGeneration of Mpc1fl/fl Mice
Mpc1+/flmouse embryonic stem cells (ESCs) of the C57Bl/6N sub-strain were
generated using a knockout-first approach (Skarnes et al., 2011) and obtained
from EUCOMM (European Conditional Mouse Mutagenesis Program). Re-
combinant mouse ESCs were injected into blastocysts and implanted into
pseudo-pregnant female mice. Chimeric offspring were crossed to WT mice
of the C57Bl/6J sub-strain to achieve germline transmission of the Mpc1fl
allele. Mpc1+/fl mice used for this study were of a background equivalent to
that of C57Bl/6N mice being backcrossed three times through C57Bl/6J mice.
Tolerance Tests, CLAMS, Nuclear Magnetic Resonance, and Serum
Analysis
Blood glucose and lactate were measured using a OneTouch UltraMini gluc-
ometer and Nova Biomedical Lactate Plus lactate meter, respectively. Dos-
ages, unless otherwise stated, were based on lean mass, prepared in sterile
water, and administered intraperitoneally: glucose tolerance test (GTT), 6-hr
fast, 2.0 g/kg; L/PTT, 18-hr fast, 3.0 g/kg, 10:1 lactate:pyruvate; QTT, 18-hr
fast, 2.0 g/kg; insulin tolerance test (ITT), 4-hr fast, 1.5 U/kg insulin (Humalin,
Eli Lilly) in 0.9% saline. Serum parameters were measured using commercially
available kits and reagents according to the manufacturers’ directions.
Traced Hyperinsulinemic-Euglycemic Clamps
WT and Mpc1 LivKO mice 20 weeks old were fasted 18 hr and clamped unre-
strained and conscious through a jugular vein catheter. Whole-body glucose
flux was traced by 0.05 mCi/min D-[3-3H]-glucose. Insulin was infused at
4 mU/kg/min. Tissue glucose uptake was traced by 10 mCi [1-14C]-2-deoxy-
D-glucose administered 45 min before clamp completion.
Mitochondrial Pyruvate Uptake Assay
Mitochondria were isolated in a manner similar to that described previously
(Rogers et al., 2011). Mitochondrial pyruvate uptake was measured by the in-
hibitor stop method (Halestrap, 1975).
Measurements of Mitochondrial Respiration
Experiments measuring mitochondrial respiration were performed using a
Seahorse Bioscience XF-96 extracellular flux analyzer in a manner similar to
that described previously (Rogers et al., 2011).
Hepatocyte Isolation and Gluconeogenesis Assay
Primary hepatocytes were serum starved overnight (rat) or for 3 hr (mouse) and
incubated inmedia containing desired substrates and inhibitors or vehicle, and
glucose production wasmeasured by samplingmedia at specified times using
the Glucose (HK) Assay Kit (Sigma).
Liver Triglyceride and Glycogen Measurements
Liver triglycerideswere extracted inamanner similar to thatpreviouslydescribed
(Folch et al., 1957) andmeasured using the Infinity TriglycerideReagent (Thermo
Scientific). Liver glycogen was measured using the acid hydrolysis approach
(PassonneauandLauderdale, 1974) andwith theGlucose (HK)AssayKit (Sigma).
Stable-Isotope Tracer Metabolomics
Glucose concentrations and 13C-mass isotopomer enrichment was deter-
mined as previously described (Sunny and Bequette, 2010). Organic and
amino acids were determined as previously described (Des Rosiers et al.,
1994; Molna´r-Perl and Katona, 2000; Sobolevsky et al., 2003).
Steady-State Metabolomics
Steady-state metabolic analysis was performed as previously reported (Jiye
et al., 2005; Cox et al., 2009).
qPCR
RNA was extracted using TRIzol (Life Technologies). RNA was reverse tran-
scribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems), followed by qPCR reactions using SYBR Green (Life Technologies).Metabolism 22, 669–681, October 6, 2015 ª2015 Elsevier Inc. 679
Data Analysis
Unless otherwise noted, all data are reported as mean ± SEM. SigmaPlot and
Microsoft Excel software were used to perform statistical analysis, which was
by t test unless otherwise stated. Significance was defined as indicated.
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